Le site du DES d'oncologie de Toulouse

Article

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

Hématologie - Publié le 23/06/2019 par Gauthier Glemarec


Brentuximab vedotin is an anti-CD30 antibody–drug conjugate that has been approved for relapsed and refractory Hodgkin’s lymphoma.


Source : NEJM 01/18